[{"id":"714db3ca-404e-4222-9a0f-e2cca6ea14dd","acronym":"","url":"https://clinicaltrials.gov/study/NCT07483567","created_at":"2026-03-28T01:36:25.975Z","updated_at":"2026-03-28T01:36:25.975Z","phase":"Phase 2","brief_title":"IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma","source_id_and_acronym":"NCT07483567","lead_sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 expression","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • arcotatug tavatecan (TAK-921)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 03/30/2026","start_date":" 03/30/2026","primary_txt":" Primary completion: 06/30/2030","primary_completion_date":" 06/30/2030","study_txt":" Completion: 06/30/2031","study_completion_date":" 06/30/2031","last_update_posted":"2026-03-19"},{"id":"91cef775-8b83-47e1-b58a-9bb196c93393","acronym":"","url":"https://clinicaltrials.gov/study/NCT06770439","created_at":"2025-02-26T07:01:17.629Z","updated_at":"2025-02-26T07:01:17.629Z","phase":"Phase 2","brief_title":"IBI343 Combined with Chemotherapy in Advanced Pancreatic Cancer","source_id_and_acronym":"NCT06770439","lead_sponsor":"Zhejiang University","biomarkers":" CLDN18","pipe":"","alterations":" ","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • albumin-bound paclitaxel • arcotatug tavatecan (TAK-921)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 01/01/2025","start_date":" 01/01/2025","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2025-01-13"},{"id":"b6dec22b-d68a-4e20-acd1-3c108bb7759f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06321913","created_at":"2024-03-22T02:47:21.968Z","updated_at":"2024-07-02T16:35:13.935Z","phase":"Phase 2","brief_title":"Study of IBI343 in Subjects With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma","source_id_and_acronym":"NCT06321913","lead_sponsor":"Harbin Medical University","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 expression","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • arcotatug tavatecan (TAK-921)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 03/15/2024","start_date":" 03/15/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-03-20"},{"id":"855ffc53-c4ec-447b-a6df-ba4b262664bc","acronym":"","url":"https://clinicaltrials.gov/study/NCT05458219","created_at":"2022-07-14T13:54:21.525Z","updated_at":"2024-07-02T16:36:00.552Z","phase":"Phase 1","brief_title":"A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors","source_id_and_acronym":"NCT05458219","lead_sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","biomarkers":" CLDN18","pipe":"","alterations":" ","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e arcotatug tavatecan (TAK-921)"],"overall_status":"Recruiting","enrollment":" Enrollment 210","initiation":"Initiation: 10/26/2022","start_date":" 10/26/2022","primary_txt":" Primary completion: 05/31/2024","primary_completion_date":" 05/31/2024","study_txt":" Completion: 10/31/2024","study_completion_date":" 10/31/2024","last_update_posted":"2022-11-11"}]